Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38

Benzinga Newsdesk www.benzinga.com Positive 81.4%

Neg 0% Neu 0% Pos 81.4%

Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $36 to $38.